The median progression-free survival was 6.8 months, and the median overall survival was 19.1 months. Pegylated liposomal doxorubicin (PLD) has demonstrated safety and efficacy in patients with ...

Among patients with early-stage malignant melanoma who underwent standard excision, the incidence of residual melanoma tumor cells in tissue from a wide local excision was low, at less than 5% of ...

Results of a retrospective study of a racially diverse population demonstrated positive outcomes for patients with NSCLC who experience irAEs when treated with immune checkpoint inhibitors.

A retrospective study revealed differences in metastasis patterns and treatment utilization by ethnicity among patients with breast cancer and brain metastasis.

The predictive model demonstrated an 8-year cumulative incidence of TKI failure in the training set of 10% in the low-risk group, 34% in the intermediate risk, and 69% in the high-risk. In the ...

All patients receiving surgery/radiotherapy alone or with chemotherapy had improvement or stability of alopecia with LDOM.